Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study
MS Journal, July 9, 2021 https://geneuro.ch/data/news/MSJ-July-21-Efficacy-and-safety-of-temelimab-in-multiple-sclerosis.pdf
GeNeuro presents data supporting pathogenic role of an endogenous retroviral protein (HERV-W ENV) in post-COVID neuropsychiatric syndrome Enters collaboration with the FondaMental Foundation to speed development of diagnostic and therapeutic…
Paris, France and Geneva, Switzerland, July 5, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), presented new data showing that the neuropsychiatric symptomatology seen in “post-COVID” patients may be due to activation of HERV-W ENV expression in […]
GeNeuro and CIRI Renew Collaboration Agreement and Expand Focus to Post-COVID Syndromes
Geneva, Switzerland, June 24, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), and the CIRI (International Center for Infectiology Research), in Lyon, France, a world-class research institute against infectious diseases, announced today the signing of an extension […]
GeNeuro Announces Approval of all Resolutions Proposed at 2021 Annual General Meeting
Geneva, Switzerland, June 1, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that its shareholders have approved all resolutions proposed at its Annual General Meeting (AGM) of May 27, 2021. These included among others: https://geneuro.ch/data/news/GeNeuro-AGM-01062021-EN-1-.pdf
Availability of documents and information for the annual shareholders’ meeting of May 27, 2021
Geneva, Switzerland, May 6, 2021 – 6:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurologic and autoimmune diseases, including multiple sclerosis, informs its shareholders that the Annual General Meeting will be held on Thursday May 27, 2021 at 9.30am at its head office, 3, chemin du Pré-Fleuri, 1228 […]
Researchers Detect HERV-W ENV in COVID-19 Patients and Link Expression to Disease Severity
Data published in the Lancet’s EBioMedicine shows that the pathogenic envelope protein of the human endogenous retrovirus W (HERV-W ENV) is found on lymphocytes of hospitalized patients with COVID-19, and that its level of expression is associated with disease severity. https://geneuro.ch/data/news/GeNeuro-HERV-and-Covid-ENG-April-15-2021.pdf
GeNeuro : financial information for the first quarter 2021
Geneva, Switzerland, April 9, 2021 – 6.00pm CEST Strong financial situation and visibility: https://geneuro.ch/data/news/GeNeuro-PR-Q1-2021-EN.pdf
GeNeuro Reports 2020 Full-Year Results and Provides Corporate Update
Geneva, Switzerland, April 6, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a clinical-stage biopharmaceutical company leveraging the biology of human endogenous retroviruses (HERVs) to develop new treatments to stop the progression of neurodegenerative and autoimmune diseases, reported today its full-year results for the year ended December 31, 2020 and provided a corporate […]
GeNeuro’s temelimab Phase 2 multiple sclerosis trial cleared to continue following planned Data Safety Monitoring Board Meeting
Geneva, Switzerland, March 2, 2021 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that the independent Drug Safety Monitoring Board (DSMB) has concluded the Phase 2 trial of temelimab in MS […]
GeNeuro completes patient recruitment in temelimab Phase 2 multiple sclerosis trial at the Karolinska Institutet’s Academic Specialist Center (ASC)
Geneva, Switzerland, January 11, 2021 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced its cash position at December 31, 2020, issued a business update and provided an outlook on its 2021 activities. https://geneuro.ch/data/news/PR-GeNeuro-MS-Study-Enrollment-Complete-EN-021821-VF.pdf